Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2026-04-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (立信会计师事务所) for auditing services for the fiscal year 2026. It details the qualifications, independence, and integrity of the accounting firm and the audit team, as well as the audit fees and the approval process by the board and audit committee. The document does not contain any financial statements or audit reports themselves but is a formal announcement of the intention to rehire the auditor, pending shareholder approval at the 2025 annual general meeting. The document length is 4218 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits best under the category of Audit Report / Information (AR) as it relates to audit firm appointment and audit-related disclosures, but since it is not the audit report itself, it is more specifically an announcement about audit firm reappointment. However, given the definitions, the closest and most appropriate classification is AR (Audit Report / Information) because it is about audit-related information and not a full annual report or other category. It is not a Regulatory Filing (RNS) because it is a substantive announcement about audit firm reappointment, not a mere certification or compliance filing. FY 2026
2026-04-28 Chinese
2025年度独立董事述职报告 （邵春阳）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the director's duties, attendance at board and committee meetings, opinions on company matters, communication with auditors, and overall governance activities during the year. It references compliance with company law, securities law, and stock exchange rules, and discusses governance and supervisory roles rather than financial results or audit opinions. The document is a detailed report on the independent director's management and governance activities for the year, which fits the category of Board/Management Information (MANG). It is not an annual report (10-K), audit report (AR), or other financial report. The length and content confirm it is a substantive report, not a brief announcement or certification. Therefore, the appropriate classification is MANG with high confidence.
2026-04-28 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an "internal control evaluation report verification opinion" for the year 2025 by CITIC Securities regarding Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It discusses the internal control evaluation scope, methodology, conclusions, and compliance with regulatory requirements. The document is detailed and contains substantive content about internal control evaluation, including financial and non-financial control defect standards, risk assessment, governance, and audit committee roles. It is not a full annual report or earnings release but a specialized audit-related report focusing on internal control evaluation. It is not a mere announcement or certification but a comprehensive report on internal control evaluation results. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2025
2026-04-28 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, and management of compensation for the company's board members and senior executives. It references relevant laws and governance codes, outlines salary composition, performance evaluation, payment, and adjustment mechanisms. There is no financial data, earnings, or audit information presented. The document is a policy or governance document specifically about remuneration. This matches the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document length is about 3006 characters, consistent with a detailed policy document rather than a brief announcement or a full annual report. Therefore, the correct classification is DEF 14A with high confidence.
2026-04-28 Chinese
董事、高级管理人员离职管理制度
Governance Information Classification · 95% confidence The document is titled '董事、高级管理人员离职管理制度' which translates to 'Board and Senior Management Resignation Management System'. It details the rules, procedures, and obligations related to the resignation and departure of company directors and senior management personnel. The content includes governance policies, legal references, and internal company rules regarding management changes but does not report on actual changes or financial results. It is a governance-related internal policy document rather than an announcement, report, or regulatory filing about specific personnel changes or financial data. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3055 characters, indicating it is a substantive policy document rather than a brief announcement or certification. Hence, the classification is CGR with high confidence.
2026-04-28 Chinese
董事会薪酬与考核委员会关于作废2024年限制性股票激励计划部分已授予尚未归属的限制性股票的核查意见
Remuneration Information Classification · 95% confidence The document is an official announcement from the Board's Remuneration and Assessment Committee regarding the cancellation of part of the 2024 restricted stock incentive plan. It discusses compliance with relevant laws and company regulations, and the cancellation of unvested restricted shares due to employee departures and unmet performance targets. The content focuses on executive compensation and stock incentive plan adjustments, which aligns with remuneration information filings. The document is short and formal, not a full report or financial statement, but a specific remuneration-related announcement.
2026-04-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.